长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的随机对照临床研究

背景与目的 长春瑞滨联合顺铂是治疗晚期非小细胞肺癌(NSCLC)的主要化疗方案之一,但副反应较重。本研究的目的是比较长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的临床疗效和毒副作用。方法 126例不能手术或术后复发转移的Ⅲ~Ⅳ期NSCLC患者随机分组,接受长春瑞滨联合顺铂或长春瑞滨联合奥沙利铂方案,化疗2~3个周期后评价疗效。结果 长春瑞滨联合顺铂组有效率为48.4%,部分缓解率为45.2%;长春瑞滨联合奥沙利铂组有效率为42.2%,部分缓解率为40.6%,两组近期疗效比较无显著性差异(P〉0.05)。长春瑞滨联合顺铂组Ⅲ+Ⅳ度白细胞下降25例(40.3%),长春瑞滨联合奥沙利铂组...

Full description

Saved in:
Bibliographic Details
Published inZhongguo fei ai za zhi Vol. 9; no. 1; pp. 71 - 73
Main Author 王晓华 侯梅 曹丹 勾红峰 杨雨
Format Journal Article
LanguageChinese
Published 610041,成都,四川大学华西医院肿瘤中心化疗科 2006
Subjects
Online AccessGet full text
ISSN1009-3419
1999-6187

Cover

Abstract 背景与目的 长春瑞滨联合顺铂是治疗晚期非小细胞肺癌(NSCLC)的主要化疗方案之一,但副反应较重。本研究的目的是比较长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的临床疗效和毒副作用。方法 126例不能手术或术后复发转移的Ⅲ~Ⅳ期NSCLC患者随机分组,接受长春瑞滨联合顺铂或长春瑞滨联合奥沙利铂方案,化疗2~3个周期后评价疗效。结果 长春瑞滨联合顺铂组有效率为48.4%,部分缓解率为45.2%;长春瑞滨联合奥沙利铂组有效率为42.2%,部分缓解率为40.6%,两组近期疗效比较无显著性差异(P〉0.05)。长春瑞滨联合顺铂组Ⅲ+Ⅳ度白细胞下降25例(40.3%),长春瑞滨联合奥沙利铂组仅10例(15.6%),两组比较有显著性差异(P<0.05);Ⅲ+Ⅳ度消化道反应在长春瑞滨联合顺铂组为11例(17.7%),长春瑞滨联合奥沙利铂组仅3例(4.7%),亦有显著性差异(P〈0.05)。长春瑞滨联合顺铂组发生神经毒性7例(11.7%),长春瑞滨联合奥沙利铂组有60例(93.8%),有显著性差异(P〈0.05)。结论 长春瑞滨联合顺铂和长春瑞滨联合奥沙利铂是治疗晚期NSCLC较有效的方案。与长春瑞滨联合顺铂方案相比,长春瑞滨联合奥沙利铂方案疗效相似,消化道反应及血液学毒性较轻,而神经毒性反应发生率较高。
AbstractList 背景与目的 长春瑞滨联合顺铂是治疗晚期非小细胞肺癌(NSCLC)的主要化疗方案之一,但副反应较重。本研究的目的是比较长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的临床疗效和毒副作用。方法 126例不能手术或术后复发转移的Ⅲ~Ⅳ期NSCLC患者随机分组,接受长春瑞滨联合顺铂或长春瑞滨联合奥沙利铂方案,化疗2~3个周期后评价疗效。结果 长春瑞滨联合顺铂组有效率为48.4%,部分缓解率为45.2%;长春瑞滨联合奥沙利铂组有效率为42.2%,部分缓解率为40.6%,两组近期疗效比较无显著性差异(P〉0.05)。长春瑞滨联合顺铂组Ⅲ+Ⅳ度白细胞下降25例(40.3%),长春瑞滨联合奥沙利铂组仅10例(15.6%),两组比较有显著性差异(P<0.05);Ⅲ+Ⅳ度消化道反应在长春瑞滨联合顺铂组为11例(17.7%),长春瑞滨联合奥沙利铂组仅3例(4.7%),亦有显著性差异(P〈0.05)。长春瑞滨联合顺铂组发生神经毒性7例(11.7%),长春瑞滨联合奥沙利铂组有60例(93.8%),有显著性差异(P〈0.05)。结论 长春瑞滨联合顺铂和长春瑞滨联合奥沙利铂是治疗晚期NSCLC较有效的方案。与长春瑞滨联合顺铂方案相比,长春瑞滨联合奥沙利铂方案疗效相似,消化道反应及血液学毒性较轻,而神经毒性反应发生率较高。
R734.2%R730.53; 背景与目的长春瑞滨联合顺铂是治疗晚期非小细胞肺癌(NSCLC)的主要化疗方案之一,但副反应较重.本研究的目的是比较长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的临床疗效和毒副作用.方法126例不能手术或术后复发转移的Ⅲ~Ⅳ期NSCLC患者随机分组,接受长春瑞滨联合顺铂或长春瑞滨联合奥沙利铂方案,化疗2~3个周期后评价疗效.结果长春瑞滨联合顺铂组有效率为48.4%,部分缓解率为45.2%;长春瑞滨联合奥沙利铂组有效率为42.2%,部分缓解率为40.6%,两组近期疗效比较无显著性差异(P>0.05).长春瑞滨联合顺铂组Ⅲ+Ⅳ度白细胞下降25例(40.3%),长春瑞滨联合奥沙利铂组仅10例(15.6%),两组比较有显著性差异(P<0.05);Ⅲ+Ⅳ度消化道反应在长春瑞滨联合顺铂组为11例(17.7%),长春瑞滨联合奥沙利铂组仅3例(4.7%),亦有显著性差异(P<0.05).长春瑞滨联合顺铂组发生神经毒性7例(11.7%),长春瑞滨联合奥沙利铂组有60例(93.8%),有显著性差异(P<0.05).结论长春瑞滨联合顺铂和长春瑞滨联合奥沙利铂是治疗晚期NSCLC较有效的方案.与长春瑞滨联合顺铂方案相比,长春瑞滨联合奥沙利铂方案疗效相似,消化道反应及血液学毒性较轻,而神经毒性反应发生率较高.
Author 王晓华 侯梅 曹丹 勾红峰 杨雨
AuthorAffiliation 四川大学华西医院肿瘤中心化疗科,成都610041
AuthorAffiliation_xml – name: 610041,成都,四川大学华西医院肿瘤中心化疗科
Author_FL HOU Mei
GOU Hongfeng
YANG Yu
WANG Xiaohua
CAO Dan
Author_FL_xml – sequence: 1
  fullname: WANG Xiaohua
– sequence: 2
  fullname: HOU Mei
– sequence: 3
  fullname: CAO Dan
– sequence: 4
  fullname: GOU Hongfeng
– sequence: 5
  fullname: YANG Yu
Author_xml – sequence: 1
  fullname: 王晓华 侯梅 曹丹 勾红峰 杨雨
BookMark eNplj7tKA0EYhQeJYBJ9CRurhbm5O1PK4g2CFqZfZndnYmLYoEGEdIpCsPCC8ZIQvBRBUwlBJCaFL5Oddd_CgdhZnQPn4_z_yYFMVIvkDMgizrllI-ZkjIeQW4QiPgdy9XoFQhtzQrNAprff-qGXXD_q8dvPcSu-aqYvo_TmZDK8-B_FvZ4etONm3wB6ME7u7nW7o7tPWztuwU06p2nnUndH8ftXcvY6GX7Eo_PkuZX0P-fBrBLVulz40zworq0W3Q2rsL2-6a4UrGCZM0tymyDMOaMyZJwHIWRYcUqx4ziKIobN-44vkcBUKix96RPo2zYNEAuJICHJg6Vp7ZGIlIhKXqV2eBCZg16jpESjgc1siCBihlycksFuLSrtlw3ri2BPlavSwwgj23Yo-QW454Ig
ClassificationCodes R734.2%R730.53
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Randomly clinical study of vinorelbine/cisplatin and vinorelbine/oxaliplatin regimens in the treatment of advanced non-small cell lung cancer
DocumentTitle_FL Randomly clinical study of vinorelbine/cisplatin and vinorelbine/oxaliplatin regimens in the treatment of advanced non-small cell lung cancer
EISSN 1999-6187
EndPage 73
ExternalDocumentID zgfazz200601018
21216674
GroupedDBID ---
-05
04C
29R
2B.
2C~
2RA
2WC
3V.
5GY
5VS
6PF
92F
92I
92L
AAWTL
ABUWG
ACGFS
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVBZV
C1A
CCEZO
CDYEO
CIEJG
CQIGP
CW9
CXBCV
DIK
E3Z
EBD
EIHBH
EMOBN
EOJEC
F5P
GROUPED_DOAJ
HYE
IPNFZ
KQ8
KWQ
OBODZ
OK1
PIMPY
PQEST
PQQKQ
PQUKI
PROAC
RIG
RNS
RPM
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
CCPQU
PGMZT
PHGZM
PHGZT
PMFND
PSX
ID FETCH-LOGICAL-c598-e963129984ed899cd082f9442777f41824197be1a24ef2ebeb30b664c18d3a3d3
ISSN 1009-3419
IngestDate Thu May 29 03:56:16 EDT 2025
Fri Nov 25 17:05:47 EST 2022
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords 长春瑞滨
顺铂
非小细胞肺癌
草酸铂
随机试验
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c598-e963129984ed899cd082f9442777f41824197be1a24ef2ebeb30b664c18d3a3d3
Notes Non-small cell lung cancer Random trial Vinorelbine Cisplatin Oxaliplatin
R730.53
R734.2
12-1395/R
PageCount 3
ParticipantIDs wanfang_journals_zgfazz200601018
chongqing_backfile_21216674
PublicationCentury 2000
PublicationDate 2006
PublicationDateYYYYMMDD 2006-01-01
PublicationDate_xml – year: 2006
  text: 2006
PublicationDecade 2000
PublicationTitle Zhongguo fei ai za zhi
PublicationTitleAlternate Chinese Journal of Lung Cancer
PublicationTitle_FL CHINESE JOURNAL OF LUNG CANCER
PublicationYear 2006
Publisher 610041,成都,四川大学华西医院肿瘤中心化疗科
Publisher_xml – name: 610041,成都,四川大学华西医院肿瘤中心化疗科
SSID ssj0062934
ssib002262905
ssib001103766
ssib038074678
ssib044765436
ssib051369142
Score 1.706264
Snippet 背景与目的 长春瑞滨联合顺铂是治疗晚期非小细胞肺癌(NSCLC)的主要化疗方案之一,但副反应较重。本研究的目的是比较长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚...
R734.2%R730.53; 背景与目的长春瑞滨联合顺铂是治疗晚期非小细胞肺癌(NSCLC)的主要化疗方案之一,但副反应较重.本研究的目的是比较长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 71
SubjectTerms 草酸铂
长春瑞滨
随机试验
非小细胞肺癌
顺铂
Title 长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的随机对照临床研究
URI http://lib.cqvip.com/qk/91098A/20061/21216674.html
https://d.wanfangdata.com.cn/periodical/zgfazz200601018
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib044765436
  issn: 1009-3419
  databaseCode: M~E
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: East & South Asia Database
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BVBZV
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eastsouthasia
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BENPR
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LahRBcIgRxIv4xBiVHOzjyDx6-nHs2cwSxATRCLmFeSYgbFCTy94UheDBB8ZHQvBxCJqTEERicvAn_ITsrPsXVvVMZsdEiAaWoamqruf2VO3sVLdhXGEscSmLmRnZiWPSmKZmlNqhGcaMW6kTW0Jig_P4BBu7Ta9NeVMDR37W3lpamI-uxu2_9pUcJqoAg7hil-x_RLZiCgAYQ3zhChGG6z_FmASSSI_4TRIwIgVRHgk4kTaRAUJ8nyhBAgHVIpGUBB6RFhECZymb-EpPd4lwSECJD2TBYRl6SInEQOMQKRECcCVrIjQKOCBDYM61CMAqPWgQ2Zy41bje0HhFBNVTYdAs8agvCGkSXyKNgDEvFfe1LkAgFKKUpbXjKN9n9fK7pFejWnef-KPaGkcz56iOaGhxo1pl7QlZZWotNiDC31Xd1XYCbdAnAQEBagkkyiHFQUEFhmmJcldn2cd4yBOmAX9QRBWSXeJbfz6TqdYPww34IAVpXcHPEAVwlnDRHgRq2-CDbDgag46j2l8eGq9YpTjar4qIe2g8BkiicahF4Zqmdo1ADnX3AVy45SwIaD-sHAUVh6OV6Q7_GsMd_er5UO5b9kVuK47KKauk4vyZPVuVt2eysN129B4_lo0d-FD-WoPGUT-YuHGzX6Vjb2r9qYHDHNlPO3gEAqTvKi1QyrEBuqL3bJdJm1a7xMHk4uWRXWNwm5TZudbMXSj-dC9eKwtbM7WycfKkcaL8vTeiisV7yhhoz542jo2Xb7ScMdLeqx_527Xui3f59udfD5Y6zxd7H7d6Lx_ubD7dj-qsreUby53FdSDIN7a7r9_kyyv56nu9crorj3orz_LVrc6X793Hn3Y2v3a2nnQ_LHXXv501JpvBZGPMLI8-MWNPCjOFtAiFuBQ0TYSUcQKFeiYpdTjnGbUFlN2S4z3VoWnmwH04cq2IMRrbInFDN3HPGYOtuVZ63hhJrNBywIFOlnk0C8OIgYusNIySKKMWZ0PGcOUsqJzjO7gf3DQUtDZjnA4ZI6X7psv73v3pPVG-cDDJsHG8_-TyojE4f28hvQS1_Hx0ufxu_AZau8VJ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%95%BF%E6%98%A5%E7%91%9E%E6%BB%A8%E8%81%94%E5%90%88%E9%A1%BA%E9%93%82%E4%B8%8E%E9%95%BF%E6%98%A5%E7%91%9E%E6%BB%A8%E8%81%94%E5%90%88%E5%A5%A5%E6%B2%99%E5%88%A9%E9%93%82%E6%B2%BB%E7%96%97%E6%99%9A%E6%9C%9FNSCLC%E7%9A%84%E9%9A%8F%E6%9C%BA%E5%AF%B9%E7%85%A7%E4%B8%B4%E5%BA%8A%E7%A0%94%E7%A9%B6&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%82%BA%E7%99%8C%E6%9D%82%E5%BF%97&rft.au=%E7%8E%8B%E6%99%93%E5%8D%8E&rft.au=%E4%BE%AF%E6%A2%85&rft.au=%E6%9B%B9%E4%B8%B9&rft.au=%E5%8B%BE%E7%BA%A2%E5%B3%B0&rft.date=2006&rft.pub=610041%2C%E6%88%90%E9%83%BD%2C%E5%9B%9B%E5%B7%9D%E5%A4%A7%E5%AD%A6%E5%8D%8E%E8%A5%BF%E5%8C%BB%E9%99%A2%E8%82%BF%E7%98%A4%E4%B8%AD%E5%BF%83%E5%8C%96%E7%96%97%E7%A7%91&rft.issn=1009-3419&rft.volume=9&rft.issue=1&rft.spage=71&rft.epage=73&rft.externalDocID=zgfazz200601018
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91098A%2F91098A.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgfazz%2Fzgfazz.jpg